论文部分内容阅读
目的探讨胆囊良恶性病变组织中泛素和cul-1(cullin-1)的表达水平及其临床病理意义。方法将108例胆囊腺癌,46例癌旁组织,15例腺瘤性息肉和35例慢性胆囊炎手术切除标本常规制作石蜡包埋切片;泛素和cul-1染色方法采用EnVsionTM免疫组化法。结果胆囊腺癌泛素和cul-1表达阳性率分别为51.9%和48.1%,明显高于癌旁组织的21.7%和15.2%,腺瘤性息肉的13.3%和6.7%,以及慢性胆囊炎胆囊上皮的2.9%和0.0%(均P<0.01)。泛素和cul-1阳性的胆囊良性病变胆囊上皮均呈不典型增生;高分化腺癌和无淋巴结转移病例泛素表达阳性率明显低于中、低分化腺癌和淋巴结转移者(P<0.05);高分化腺癌、肿块最大径<2cm者、无淋巴结转移和未侵犯周围组织者的cul-1表达阳性率明显低于低分化腺癌、肿块最大径≥2cm者、淋巴结转移及侵犯周围组织者(P<0.05或P<0.01)。胆囊腺癌中泛素与cul-1表达水平存在高度一致性(P<0.01)。结论泛素及cul-1表达与胆囊腺癌发生、进展、临床生物学行为和预后存在密切的关系。
Objective To investigate the expression of ubiquitin and cul-1 (cullin-1) in benign and malignant lesions of gallbladder and its clinicopathological significance. Methods 108 cases of gallbladder adenocarcinoma, 46 cases of paracancerous tissue, 15 cases of adenomatous polyps and 35 cases of chronic cholecystitis were routinely prepared paraffin-embedded sections; ubiquitin and cul-1 staining using EnVsionTM immunohistochemistry . Results The positive rates of ubiquitin and cul-1 in gallbladder adenocarcinoma were 51.9% and 48.1%, respectively, which were significantly higher than those in paracancerous tissues (21.7% and 15.2%), adenoma (13.3% and 6.7%), and chronic cholecystitis Epithelial 2.9% and 0.0% (all P <0.01). Ubiquitin and cul-1 positive gallbladder benign lesions gallbladder epithelium were atypical hyperplasia; well-differentiated adenocarcinoma and no lymph node metastasis ubiquitin expression was significantly lower than in moderate and poorly differentiated adenocarcinoma and lymph node metastasis (P <0.05 ); Well-differentiated adenocarcinoma, the maximum diameter of tumor <2cm, no lymph node metastasis and non-invasion of the surrounding tissue of the cul-1 positive expression rate was significantly lower than poorly differentiated adenocarcinoma, tumor maximum diameter ≥ 2cm, lymph node metastasis and surrounding Tissue (P <0.05 or P <0.01). The expression of ubiquitin and cul-1 in gallbladder adenocarcinoma was highly consistent (P <0.01). Conclusion The expression of ubiquitin and cul-1 is closely related to the occurrence, progression, clinical biological behavior and prognosis of gallbladder adenocarcinoma.